Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX2 | Q96LB1 | 4/20 | 0.58 |
| ▸ | OPRM1 | P35372 | 17/20 | 0.52 |
| ▸ | OPRK1 | P41145 | 15/20 | 0.52 |
| ▸ | OPRD1 | P41143 | 14/20 | 0.51 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.47 |
| ▸ | ARRB1 | P49407 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3019720 | 0.92 | MRGPRX2 (0.61) | MRGPRX2OPRM1OPRK1OPRD1SLC22A1 | |
| SCHEMBL3013997 | 0.88 | MRGPRX2 (0.62) | MRGPRX2OPRM1OPRK1OPRD1SLC22A1 | |
| SCHEMBL15095527 | 0.83 | OPRM1 (0.62) | MRGPRX2OPRM1OPRK1OPRD1SLC22A1 | |
| SCHEMBL13245922 | 0.83 | OPRM1 (0.62) | MRGPRX2OPRM1OPRK1OPRD1SLC22A1 | |
| SCHEMBL4081399 | 0.81 | MRGPRX2 (0.68) | MRGPRX2OPRM1OPRK1OPRD1SLC22A1 | |
| SCHEMBL3123600 | 0.78 | MRGPRX2 (0.62) | MRGPRX2OPRM1OPRK1OPRD1SLC22A1 | |
| SCHEMBL6865984 | 0.77 | MRGPRX2 (0.62) | MRGPRX2OPRM1OPRK1OPRD1SLC22A1 | |
| SCHEMBL5108293 | 0.77 | MRGPRX2 (0.77) | MRGPRX2OPRM1OPRK1OPRD1 | |
| SCHEMBL3132180 | 0.76 | MRGPRX2 (0.63) | MRGPRX2OPRM1OPRK1OPRD1SLC22A1 | |
| Methoxymethane SCHEMBL27466715 | 0.76 | MRGPRX2 (0.94) | MRGPRX2OPRM1OPRK1OPRD1SLC22A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1758452-B1 | METABOLICALLY STABLE ANALGESICS AND PAIN MEDICATIONS | HUMAN BIOMOLECULAR RES INST (US) | 2017-01-25 | — | — | EP | disclosed |
| US-8481501-B2 | Synthesis of metabolically stable analgesics, pain medications and other agents | HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) | 2013-07-09 | — | — | US | disclosed |
| US-20100190728-A1 | Synthesis Of Metabolically Stable Analgesics, Pain Medications And Other Agents | HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) | 2010-07-29 | — | — | US | disclosed |
| EP-1758452-A4 | SYNTHESIS OF METABOLICALLY STABLE ANALGESICS, PAIN MEDICATIONS AND OTHER AGENTS | HUMAN BIOMOLECULAR RES INST (US) | 2009-08-05 | — | — | EP | disclosed |
| EP-1758452-A1 | SYNTHESIS OF METABOLICALLY STABLE ANALGESICS, PAIN MEDICATIONS AND OTHER AGENTS | Human Biomolecular Research Institute (US) | 2007-03-07 | — | — | EP | disclosed |
| WO-2005117589-A1 | SYNTHESIS OF METABOLICALLY STABLE ANALGESICS, PAIN MEDICATIONS AND OTHER AGENTS | HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) | 2005-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190728-A1 | Synthesis Of Metabolically Stable Analgesics, Pain Medications And Other Agents | OPRK1, OPRL1, OPRM1 | MRGPRX2 206/4885OPRM1 3/4885OPRK1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.